UK markets closed

ROCHE HOLDING AG ROCHE HOLDING (0QQ6.IL)

IOB - IOB Delayed price. Currency in CHF
Add to watchlist
310.400.00 (0.00%)
At close: 4:19PM BST
Full screen
Previous close310.40
Open312.80
Bid0.00 x N/A
Ask0.00 x N/A
Day's range309.20 - 313.40
52-week range299.60 - 413.40
Volume825
Avg. volume294
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Roche Extraordinary General Meeting 2021

    All proposals of the Board of Directors approved Audited statutory interim financial statements (standalone financial statements) of the Company as of 31 October 2021 approved Share capital reduction by cancellation of 53,309,000 bearer shares with a nominal value of CHF 1 each approved Basel, 26 November 2021 – On 4 November 2021, Roche (SIX: RO, ROG; OTCQX: RHHBY) had announced its agreement with Novartis Holding AG (Novartis) regarding the repurchase of the equity stake held by Novartis in Ro

  • Business Wire

    Genentech to Present New Pivotal Data at ASH 2021 From Broad and Comprehensive Portfolio, Challenging Treatment Standards for People With Blood Disorders

    SOUTH SAN FRANCISCO, Calif., November 23, 2021--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data from its extensive hematology portfolio will be presented at the American Society of Hematology (ASH) Annual Meeting and Exposition from December 11-14, 2021. Genentech molecules will be featured in more than 90 abstracts, including 17 oral presentations, showcasing new immunotherapies, unique treatment combinations, the application of novel endpoints,

  • Globe Newswire

    Roche to present new pivotal data at ASH 2021 from broad and comprehensive portfolio, challenging treatment standards for people with blood disorders

    Phase III POLARIX trial showed Polivy plus R-CHP was the first treatment in two decades to significantly improve outcomes in newly diagnosed diffuse large B-cell lymphoma (DLBCL) versus the standard of care1Pivotal data on mosunetuzumab, a potential first-in-class CD20xCD3 T-cell engaging bispecific antibody, showed high response rates in relapsed or refractory follicular lymphoma (FL)2HAVEN 6 phase III interim data demonstrated Hemlibra’s favourable safety and efficacy profile in people with mo